# Exploring Peptide Therapies for Amyotrophic Lateral Sclerosis (ALS): Current Research and Anecdotal Use

Canonical source: https://retacompare.com/research/peptides-for-amyotrophic-lateral-sclerosis-als-what-s-being-researched

Peptides for Disease — Overview · 2026-05-03


    This article surveys the peptide therapy landscape for Amyotrophic Lateral Sclerosis (ALS), highlighting peptides under investigation, those with anecdotal use, and the limited FDA-approved options available.


The big picture

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord, leading to muscle weakness and atrophy. The exact cause of ALS remains unclear, and there is currently no cure. Treatment options primarily focus on symptom management and extending survival. Peptide therapies have emerged as a potential area of interest, with various peptides being studied for their neuroprotective and regenerative properties. For broader context, see the broader research library and our peptide stacking guide.


What the clinical evidence shows

Currently, the clinical evidence for peptide therapies specifically targeting ALS is limited. However, some peptides are being investigated for their potential benefits. For example, IGF-1 (Insulin-like Growth Factor 1) analogs have been studied for their neuroprotective effects in various neurodegenerative conditions. Additionally, Cerebrolysin, a mixture of neuropeptides, has shown promise in some studies for cognitive improvement in neurodegenerative diseases, although it is not FDA-approved in the US. Preclinical studies have suggested that Semaglutide, a GLP-1 receptor agonist, may have neuroprotective effects, but more research is needed to establish its efficacy in ALS.


What the community reports anecdotally

Anecdotal reports from patients and biohacker communities suggest that some individuals have explored the use of peptides like Cerebrolysin and others not FDA-approved for ALS management. Users report varying experiences, with some claiming improvements in muscle strength and overall well-being. However, it is crucial to note that these self-reported benefits are not supported by controlled clinical trials, and no formal evidence confirms their effectiveness. The use of peptides like BPC-157 and TB-500 has also been discussed in forums, with users sharing personal accounts of their experiences, but again, these claims lack rigorous scientific validation.


Key points at a glance

ALS is a progressive neurodegenerative disorder with no known cure.

Peptides like IGF-1 analogs and Cerebrolysin are being studied for neuroprotective effects.

Semaglutide is under investigation for potential neuroprotective properties.

No peptide therapies for ALS are FDA-approved in the US.

Anecdotal reports from users highlight personal experiences but lack scientific validation.

Clinical evidence is limited and primarily hypothesis-driven.

Patients should approach peptide therapies with caution due to the lack of regulatory approval.


Safety and what to watch for

The safety of peptides used for ALS is not well established, particularly for those not FDA-approved. Potential side effects can vary widely depending on the peptide in question. Users of unregulated peptides may experience unknown risks, including adverse reactions or interactions with other medications. It is essential to approach these substances with caution and to consult healthcare professionals before considering their use.


Open questions

Significant gaps remain in the understanding of how peptides can be effectively utilized in ALS. Future research is needed to explore the mechanisms by which peptides may exert neuroprotective effects and to establish the safety and efficacy of these therapies through controlled clinical trials. Regulatory uncertainty also persists, as many promising peptides are not yet approved for use in the US.


Bottom line

While peptides represent a potential avenue for ALS research, the current landscape is characterized by limited clinical evidence and a predominance of anecdotal reports. Caution is advised for those considering peptide therapies.


This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Amyotrophic Lateral Sclerosis (ALS) or any indication. Do not start or change therapy without consulting a qualified clinician.

## Sources